Baxalta
Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. The company began its operation with a revenue of $6 billion, and is now a subsidiary of Takeda Pharmaceutical Company.
Basic Information
- Category: Pharmaceutical companies
- Website: http://www.baxalta.com/
Documented Facts
- Email: media_relations@takeda.com (No linked source recorded for this statement.)
- Revenue: $6 billion (No linked source recorded for this statement.)
- Parent company: Takeda Pharmaceutical Company (No linked source recorded for this statement.)
Evidence and Sources
- Baxalta — Wikipedia (reference)
Citation Guidance
Explore Pharmaceutical companies profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Baxalta.
- Canonical profile: https://brandsource.ai/brands/baxalta
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/baxalta/json-ld
- Citation profile API: https://brandsource.ai/api/brands/baxalta/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (73/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-23
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. The company began its operation with a revenue of $6 billion, and is now a subsidiary of Takeda Pharmaceutical Company.
Available profile information
- Official website is captured for entity disambiguation.
- 1 supporting source linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.